|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Patterns of somatic mutation in human cancer genomes.
|
17344846 |
2007 |
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.
|
18931684 |
2008 |
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.
|
11807987 |
2002 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further studies are needed to establish the benefit of KDR mutation as predictive marker for regorafenib sensitivity for patients with CRC.
|
29924031 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
|
23146028 |
2012 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
|
29588308 |
2018 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.
|
19723655 |
2009 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Likewise, activating mutations in the receptor tyrosine kinase KDR (VEGFR2) have been reported in angiosarcomas and non-small cell lung cancers; the KDR A1065T mutation is reported to be sensitive to VEGFR kinase inhibitors, and fibroblast growth factor receptor inhibitors are in trials.
|
25679062 |
2015 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Mutations in KDR have been reported previously in angiosarcomas.
|
28056866 |
2017 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Recurrent MYC amplifications (96%) and KDR variants (8%) were detected in post-radiation angiosarcomas, in agreement with the literature.
|
31243333 |
2019 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
The p.T771R mutation was previously implicated in autophosphorylation of VEGFR2 and reported in angiosarcomas alongside other driver mutations.
|
26422291 |
2015 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification.
|
29855279 |
2018 |
|
Hemangiosarcoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Together, these findings indicate that the PLCγ1-R707Q mutation causes constitutive activation of PLCγ1 and may represent an alternative way of activation of KDR/PLCγ1 signaling besides KDR activation in angiosarcomas, with implications for VEGF/KDR targeted therapies.
|
25252913 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KDR inferred haplotype is associated with upper limb dysfunction in breast cancer survivors of mixed ancestry.
|
31118800 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It was found that both rare homozygotes in the ANLN:rs12535394 and KDR:rs11133360 SNP pair are prognostic of favorable breast cancer survival and underpin the prominent roles of the immune response in cancer state control.
|
31578580 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated dietary factors associated with oxidative balance, DDIT4 (one SNP), FLT1 (35 SNPs), HIF1A (four SNPs), KDR (19 SNPs), MPO (one SNP), NOS2A (15 SNPs), TEK (40 SNPs) and VEGFA (eight SNPs) and breast cancer risk among Hispanic (2,111 cases and 2,597 controls) and non-Hispanic white (1,481 cases and 1,586 controls) women in the Breast Cancer Health Disparities Study.
|
23832257 |
2014 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Published data search up to November 2018 reporting peripheral neuropathy in patients with cancer treated with VEGFR-TKIs was performed.
|
31167931 |
2019 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Single-nucleotide polymorphisms (SNPs) of KDR have been reported to be with the risk and prognosis of several malignancies.
|
25123269 |
2014 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genotyping for germline variants in KDR may have clinical utility in identifying patients with cancer with unusual sensitivity to effects of VEGFR2 kinase inhibitors.
|
25411163 |
2015 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Importantly, we discovered that VEGFR2 is somatically mutated across tumor types and that VEGFR2 mutants can be oncogenic and control sensitivity/resistance to antiangiogenic drugs.<i>Clin Cancer Res; 24(15); 3550-9.©2018 AACR</i>.
|
29588308 |
2018 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
VEGF/VEGFR inhibitor therapy was independently associated with improvement in all outcome parameters [rate of stable disease (SD) ≥6 months/partial and complete remission (PR/CR); (31% versus 7%; TP53-mutant patients (who received no other molecular-matched agents) treated with versus without VEGF/VEGFR inhibitors), time-to-treatment failure, and overall survival (multivariate analysis: all P ≤ 0.01)] for the patients harboring TP53-mutant cancers, but improvement was not seen in any of these parameters for patients with TP53 wild-type neoplasms.
|
27466356 |
2016 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our data support the integration of germline analysis into personalized treatment decision-making and suggest that patients with germline KDR variant might benefit from antiangiogenesis treatment.Clin Cancer Res; 22(10); 2377-85.©2015 AACR.
|
26631613 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
|
25975224 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the characteristics of the -271 G>A polymorphism of the KDR gene to gain information that may benefit the development of individualized therapies for patients with non-small cell lung cancer (NSCLC).
|
19435508 |
2009 |